XML 37 R29.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaborative Research, Development, and License Agreements - Additional Information (Detail) (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  | 12 Months Ended |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |  | 1 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended |  |  |  |  |  | 1 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2008 Glaxo, Smith, Kline Project | Sep. 30, 2013 Glaxo, Smith, Kline | Sep. 30, 2012 Glaxo, Smith, Kline | Sep. 30, 2013 Glaxo, Smith, Kline | Sep. 30, 2012 Glaxo, Smith, Kline | Dec. 31, 2011 Glaxo, Smith, Kline | Dec. 31, 2012 Glaxo, Smith, Kline | Dec. 31, 2011 Glaxo, Smith, Kline Expansion | Sep. 30, 2013 Glaxo, Smith, Kline Maximum | Sep. 30, 2013 Glaxo, Smith, Kline Maximum Annual net sales milestones achieved | Sep. 30, 2006 Astra Zeneca | Sep. 30, 2013 Astra Zeneca | Sep. 30, 2012 Astra Zeneca | Sep. 30, 2013 Astra Zeneca | Sep. 30, 2012 Astra Zeneca | Dec. 31, 2012 Astra Zeneca | Oct. 31, 2011 Amendment | Dec. 31, 2011 Amendment | Dec. 31, 2012 Amendment Advance the program following completion of Phase 2a | Mar. 31, 2012 Amendment Advance the program following completion of Phase 2a | Sep. 30, 2013 Amendment Advance the program following completion of Phase 2a | Sep. 30, 2013 Amendment Maximum Advance the program following completion of Phase 2a | Jun. 30, 2012 Autoimmune Disease National Institutes of Health | May 31, 2012 Rheumatoid Arthritis National Institutes of Health | Jul. 31, 2011 Skin Autoimmune Inflammation National Institutes of Health | Aug. 31, 2010 HBV National Institutes of Health | Jul. 31, 2010 HPV National Institutes of Health | Sep. 30, 2008 ISS Technology National Institutes of Health | Sep. 30, 2013 Hepatic Fibrosis and Cirrhosis National Institutes of Health
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of programs for research and early clinical development | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  | $ 125,000,000 | $ 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Revenue | 10,000,000 | 357,000 | 357,000 | 1,071,000 | 1,071,000 |  |  |  |  |  |  | 180,000 | 180,000 | 540,000 | 540,000 |  | 3,000,000 |  | 6,000,000 | 2,600,000 |  |  |  |  |  |  |  |  |
Revenue from milestone payment |  |  |  |  |  | 12,000,000 |  | 3,000,000 |  |  |  | 573,000 | 513,000 | 1,738,000 | 1,991,000 |  |  |  |  |  | 20,000,000 | 100,000,000 |  |  |  |  |  |  |
Deferred revenue recognition period |  | 7 years |  | 7 years |  |  |  |  |  |  |  | 50 months |  | 50 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | 3,200,000 |  | 3,200,000 |  |  | 4,200,000 |  |  |  |  | 5,700,000 |  | 5,700,000 |  | 7,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Research collaboration and license agreement period |  |  |  |  |  |  |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of clinical development activities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |  |  |
Grants receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 600,000 | 400,000 | 600,000 | 1,400,000 | 600,000 |  | 200,000
Contract agreement period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |
Contract awarded to develop technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 17,000,000 |

X
- Definition Revenue from collaboration agreement. + References No definition available. + Details
Name: | dvax_CollaborationRevenue
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contract Term + References No definition available. + Details
Name: | dvax_ContractTerm
Namespace Prefix: | dvax_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Projects + References No definition available. + Details
Name: | dvax_NumberOfProjects
Namespace Prefix: | dvax_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Milestone Payment Amount + References No definition available. + Details
Name: | dvax_PotentialMilestonePaymentAmount
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research Collaboration and License Agreement Period + References No definition available. + Details
Name: | dvax_ResearchCollaborationAndLicenseAgreementPeriod
Namespace Prefix: | dvax_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Period + References No definition available. + Details
Name: | dvax_RevenueRecognitionPeriod
Namespace Prefix: | dvax_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 910 -SubTopic 310 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6471494&loc=d3e49354-109356 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3(c)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph c -Article 5 + Details
Name: | us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5 + Details
Name: | us-gaap_GrantsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration